Cephalon Expects To Reduce Modafinil Price For ADHD By About 40%
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says it will price modafinil for attention deficit/hyperactivity disorder in-line with other branded products on the market at the time of launch. Based on current prices, Cephalon expects to reduce modafinil's price for ADHD to $3-$3.50 from the current $6 per pill price for Provigil.
You may also be interested in...
Cephalon Will Add 250-Rep Pediatric Sales Force For Modafinil ADHD Launch
The firm plans two launches for early 2006: modafinil for attention deficit/hyperactivity disorder (formerly under the trade name Attenace) and Nuvigil (armodafinil) for sleep disorders. Cephalon has two additional products nearing submission.
Cephalon’s Nuvigil Filing Remains On Schedule For First Quarter
Cephalon's modafinil follow-on Nuvigil (armodafinil) showed statistical significance in each of four pivotal studies intended to support a first-quarter NDA filing, the firm announced Feb. 10
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.